Key regions: United Kingdom, Brazil, Europe, France, Canada
The prevalence of cardiovascular diseases in Egypt has been consistently on the rise in recent years, leading to an increasing demand for anti-fibrinolytic drugs.
Customer preferences: Patients in Egypt are increasingly seeking medical treatment for cardiovascular diseases, including those that require anti-fibrinolytic drugs. This trend is driven by growing awareness of the risks associated with these conditions, as well as greater access to healthcare services.
Trends in the market: The anti-fibrinolytic drugs market in Egypt is expected to experience steady growth in the coming years. This growth is driven by factors such as increasing prevalence of cardiovascular diseases, rising healthcare expenditure, and growing demand for effective treatment options. As a result, pharmaceutical companies are investing in research and development to create new and innovative anti-fibrinolytic drugs that can meet the needs of patients in Egypt.
Local special circumstances: There are several factors that are unique to the Egyptian market that are influencing the growth of the anti-fibrinolytic drugs market. One of these is the country's large and growing population, which is driving demand for healthcare services. Additionally, the government has made significant investments in the healthcare sector in recent years, which has helped to improve access to medical treatment for many Egyptians.
Underlying macroeconomic factors: The growth of the anti-fibrinolytic drugs market in Egypt is also influenced by broader macroeconomic factors. For example, the country's economic growth has been relatively strong in recent years, which has helped to drive up healthcare spending. Additionally, the government has implemented a range of policies aimed at improving healthcare outcomes, including investments in infrastructure and technology. These factors are expected to continue to support the growth of the anti-fibrinolytic drugs market in Egypt in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
